Literature DB >> 15177267

Modulation of atherogenesis by chemokines.

William A Boisvert1.   

Abstract

Migration of leukocytes into the vasculature-which involves the concerted effort of many molecules, including chemokines-is a requisite step for atherogenesis. The three chemokines that have been implicated most strongly in atherogenesis are monocyte chemoattractant protein 1 (MCP-1), interleukin 8 (IL-8)/growth-regulated oncogene alpha (Gro-alpha), and fractalkine. Although all three chemokines appear to impact atherogenesis by attenuating monocyte/macrophage accumulation in the lesion, the precise mechanism of action of each of the chemokines, as well as their interactive role in atherosclerosis, have not been elucidated. This review focuses on the latest findings that describe the individual roles of MCP-1, IL-8/Gro-alpha, and fractalkine on macrophage recruitment in atherosclerosis. Furthermore, based on present knowledge of the participation of these three chemokines and their receptors in monocyte/macrophage recruitment, a possible interactive role of these chemokines in atherogenesis is explored.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15177267     DOI: 10.1016/j.tcm.2004.02.006

Source DB:  PubMed          Journal:  Trends Cardiovasc Med        ISSN: 1050-1738            Impact factor:   6.677


  29 in total

1.  Lysophosphatidic acid effects on atherosclerosis and thrombosis.

Authors:  Mei-Zhen Cui
Journal:  Clin Lipidol       Date:  2011-08

2.  The CARMA3-Bcl10-MALT1 signalosome promotes angiotensin II-dependent vascular inflammation and atherogenesis.

Authors:  Linda M McAllister-Lucas; Xiaohong Jin; Shufang Gu; Katy Siu; Scott McDonnell; Jürgen Ruland; Phillip C Delekta; Matthew Van Beek; Peter C Lucas
Journal:  J Biol Chem       Date:  2010-07-05       Impact factor: 5.157

3.  Viable head and neck tumor spheroids stimulate in vitro autologous monocyte MCP-1 secretion through soluble substances and CD14/lectin-like receptors.

Authors:  Carla Olsnes; John-Helge Heimdal; Kenneth W Kross; Jan Olofsson; Hans Jørgen Aarstad
Journal:  Eur Arch Otorhinolaryngol       Date:  2005-11-19       Impact factor: 2.503

4.  TLR4 activation induces nontolerant inflammatory response in endothelial cells.

Authors:  Wenmeng Wang; Minjie Deng; Xueting Liu; Wen Ai; Qizhu Tang; Jinyue Hu
Journal:  Inflammation       Date:  2011-12       Impact factor: 4.092

5.  Adiponectin reduces C-reactive protein expression and downregulates STAT3 phosphorylation induced by IL-6 in HepG2 cells.

Authors:  Haiyun Sun; Yingnan Zhang; Ping Gao; Qiang Li; Yuqian Sun; Jinchao Zhang; Changqing Xu
Journal:  Mol Cell Biochem       Date:  2010-10-27       Impact factor: 3.396

6.  Emodin-6-O-β-D--glucoside inhibits high-glucose-induced vascular inflammation.

Authors:  Wonhwa Lee; Sae-Kwang Ku; Doohyun Lee; Taeho Lee; Jong-Sup Bae
Journal:  Inflammation       Date:  2014-04       Impact factor: 4.092

7.  Orientin inhibits high glucose-induced vascular inflammation in vitro and in vivo.

Authors:  Sae-Kwang Ku; Soyoung Kwak; Jong-Sup Bae
Journal:  Inflammation       Date:  2014-12       Impact factor: 4.092

8.  NHE-1 and β1 integrin dependent monocyte adhesion and migration after glucose, insulin or PPARγ stimulation.

Authors:  Zacharoula Zolota; George Koliakos; Konstantinos Paletas; Martha Kaloyianni
Journal:  Cell Adh Migr       Date:  2011-05-01       Impact factor: 3.405

9.  The endothelium-derived contracting factor uridine adenosine tetraphosphate induces P2Y(2)-mediated pro-inflammatory signaling by monocyte chemoattractant protein-1 formation.

Authors:  Mirjam Schuchardt; Jasmin Prüfer; Nicole Prüfer; Annette Wiedon; Tao Huang; Miriam Chebli; Vera Jankowski; Joachim Jankowski; Monika Schäfer-Korting; Walter Zidek; Markus van der Giet; Markus Tölle
Journal:  J Mol Med (Berl)       Date:  2011-04-13       Impact factor: 4.599

10.  Unchanged asymmetric dimethylarginine levels in non-diabetic, premenopausal obese women who have common risk factors for cardiovascular disease.

Authors:  P Cetinalp-Demircan; A Can; Selda Bekpinar; Y Unlucerci; Y Orhan
Journal:  Endocrine       Date:  2007-04       Impact factor: 3.633

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.